Literature DB >> 8058611

Pharmacodynamics of phenobarbital anesthesia and pentylenetetrazol-induced maximal seizures in a rat model of neoplastic spinal cord compression.

A Hoffman1, J Alfon, T Siegal, T Siegal.   

Abstract

The purpose of this investigation was to determine whether paraplegia induced by neoplastic cord compression affects the pharmacodynamics of phenobarbital general anesthesia or of pentylenetetrazol (PTZ)-induced convulsions. Paraplegic rats harboring a thoracolumbar epidural tumor, or an identical hindlimb tumor mass, received an i.v. infusion of phenobarbital until the onset of anesthesia. At that point, the phenobarbital concentrations in the CSF and serum were measured. Similarly, PTZ was infused until the onset of maximal seizures. It was found that changes related to systemic tumor growth and newly developed paraplegia due to neoplastic spinal cord compression did not attenuate the pharmacodynamics of phenobarbital. However, sustained paraplegia of 4 days' duration reduced CNS sensitivity to the hypnotic action of the barbiturate as evidenced by the higher cerebrospinal fluid phenobarbital concentration required to induce anesthesia (170 +/- 31 vs 125 +/- 20 mg/L; P < 0.05). On the other hand, sustained paraplegia did not affect brain threshold concentration for PTZ-induced seizures.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058611     DOI: 10.1023/a:1018914532125

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Kinetics of drug action in disease states. XXIX. Effect of experimental nephrotic syndrome on the pharmacodynamics of heptabarbital: implications of severe hypoalbuminemia.

Authors:  A Hoffman; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1989-04       Impact factor: 4.030

2.  Experimental neoplastic spinal cord compression: effect of anti-inflammatory agents and glutamate receptor antagonists on vascular permeability.

Authors:  T Siegal; T Siegal; F Lossos
Journal:  Neurosurgery       Date:  1990-06       Impact factor: 4.654

3.  Participation of serotonergic mechanisms in the pathophysiology of experimental neoplastic spinal cord compression.

Authors:  T Siegal; T Siegal
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

4.  Kinetics of drug action in disease states. XXXVII. Effects of acute fluid overload and water deprivation on the hypnotic activity of phenobarbital and the neurotoxicity of theophylline in rats.

Authors:  J G Zhi; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

5.  Experimental neoplastic spinal cord compression: evoked potentials, edema, prostaglandins, and light and electron microscopy.

Authors:  T Siegal; T Z Siegal; U Sandbank; E Shohami; J Shapira; J M Gomori; E Ben-David; R Catane
Journal:  Spine (Phila Pa 1976)       Date:  1987-06       Impact factor: 3.468

6.  Kinetics of drug action in disease states. XX. Effects of acute starvation on the pharmacodynamics of phenobarbital, ethanol and pentylenetetrazol in rats and effects of refeeding and diet composition.

Authors:  S Wanwimolruk; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1987-07       Impact factor: 4.030

7.  Kinetics of drug action in disease states. XXXVIII: Effect of body temperature on the convulsant activity of pentylenetetrazol in rats.

Authors:  J S Walker; G Levy
Journal:  J Pharm Sci       Date:  1991-10       Impact factor: 3.534

8.  Kinetics of drug action in disease states. XIV. Effect of infusion rate on pentylenetetrazol concentrations in serum, brain and cerebrospinal fluid of rats at onset of convulsions.

Authors:  I M Ramzan; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

9.  A profile of metastatic carcinoma of the spine.

Authors:  J Schaberg; B J Gainor
Journal:  Spine (Phila Pa 1976)       Date:  1985 Jan-Feb       Impact factor: 3.468

Review 10.  Spinal metastasis: current status and recommended guidelines for management.

Authors:  P Black
Journal:  Neurosurgery       Date:  1979-12       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.